Immune Suppression
28
4
7
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.6%
1 terminated out of 28 trials
92.9%
+6.4% vs benchmark
18%
5 trials in Phase 3/4
0%
0 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (28)
RSV Vaccine in Transplant Recipients
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
The Coastal Exposome: a Study of Sea Air Inhalation and Possible Links to Health
Nivolumab Combined With SOX Used in the Perioperative Treatment
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
Beet Supplementation, Exercise, Inflammation
Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes
Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Astaxanthin, Exercise Inflammation, Skin Health
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
Immun Status at Pancreatitis Patients
S100A8/A9 and Innate Immunity in Liver Disease
Cranberry Ingestion and Cycling Related Immunity and Inflammation
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
The Norwegian Prednisolone in Early Psychosis Study
Depth of Anesthesia and Proteomics